| pubmed-article:9763575 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9763575 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:9763575 | lifeskim:mentions | umls-concept:C0038317 | lld:lifeskim |
| pubmed-article:9763575 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:9763575 | lifeskim:mentions | umls-concept:C0596402 | lld:lifeskim |
| pubmed-article:9763575 | lifeskim:mentions | umls-concept:C0127400 | lld:lifeskim |
| pubmed-article:9763575 | lifeskim:mentions | umls-concept:C0332324 | lld:lifeskim |
| pubmed-article:9763575 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:9763575 | pubmed:dateCreated | 1998-11-9 | lld:pubmed |
| pubmed-article:9763575 | pubmed:abstractText | We have examined the cytotoxic effects of cyclic adenosine-3', 5'-monophosphate (cAMP) derivatives on multiple myeloma cells lines and determined that the 8-Chloro substituted derivative (8Cl-cAMP) is one of the most potent. We report here that 8Cl-cAMP is cytotoxic to both steroid sensitive and insensitive myeloma cells with a half maximal concentration of approximately 3 micromol/L. 8Cl-cAMP toxicity in myeloma cells is dependent on phosphodiesterase activity in the serum of cell culture medium. A metabolite of 8Cl-cAMP, 8-Chloro-adenosine (8Cl-AD), kills myeloma cells as effectively as 8Cl-cAMP. Adenosine deaminase (ADA) converts 8Cl-AD into 8Cl-inosine and abrogates the cytotoxic effects of 8Cl-cAMP, 8Cl-AMP, and 8Cl-AD, as does 5-(p-Nitrobenzyl)-6-Thio-Inosine (NBTI), an inhibitor of nucleoside uptake. These data suggest that 8Cl-cAMP must be converted to 8Cl-AD and that 8Cl-AD is the compound that enters the cell. Contrary to glucocorticoid-mediated cell death in myeloma cells, the pathway of 8Cl-AD-mediated cell death appears to be independent of interleukin-6 (IL-6) actions. Although the exact mode of action for this agent is currently unknown, its ability to kill steroid sensitive and insensitive multiple myeloma cells in an IL-6 independent fashion may offer exciting new therapeutic options. | lld:pubmed |
| pubmed-article:9763575 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9763575 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9763575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9763575 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9763575 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:9763575 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:9763575 | pubmed:author | pubmed-author:KrettN LNL | lld:pubmed |
| pubmed-article:9763575 | pubmed:author | pubmed-author:RosenS TST | lld:pubmed |
| pubmed-article:9763575 | pubmed:author | pubmed-author:PillaySS | lld:pubmed |
| pubmed-article:9763575 | pubmed:author | pubmed-author:TraynorA EAE | lld:pubmed |
| pubmed-article:9763575 | pubmed:author | pubmed-author:HalgrenR GRG | lld:pubmed |
| pubmed-article:9763575 | pubmed:author | pubmed-author:ZellJ LJL | lld:pubmed |
| pubmed-article:9763575 | pubmed:author | pubmed-author:HellerK FKF | lld:pubmed |
| pubmed-article:9763575 | pubmed:copyrightInfo | Copyright 1998 by The American Society of Hematology. | lld:pubmed |
| pubmed-article:9763575 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9763575 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:9763575 | pubmed:volume | 92 | lld:pubmed |
| pubmed-article:9763575 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9763575 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9763575 | pubmed:pagination | 2893-8 | lld:pubmed |
| pubmed-article:9763575 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:meshHeading | pubmed-meshheading:9763575-... | lld:pubmed |
| pubmed-article:9763575 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9763575 | pubmed:articleTitle | 8Cl-cAMP cytotoxicity in both steroid sensitive and insensitive multiple myeloma cell lines is mediated by 8Cl-adenosine. | lld:pubmed |
| pubmed-article:9763575 | pubmed:affiliation | Lurie Comprehensive Cancer Center and Department of Medicine, Northwestern University, Chicago, IL, USA. r-halgren@nwu.edu | lld:pubmed |
| pubmed-article:9763575 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9763575 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9763575 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9763575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9763575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9763575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9763575 | lld:pubmed |
